Table 2: Effects of fat distribution, glucose homeostasis, and insulin sensitivity in obese subjects after a VLCD intervention.

BaselineWeek 4Week 8Change from baseline to week 8 P

SFA, cm2348.0 ± 16.7299.4 ± 16.2264.0 ± 16.4−66.5 ± 7.9<0.0001
VFA, cm2113.9 ± 5.896.6 ± 4.979.8 ± 3.7−35.3 ± 3.9<0.0001
Liver fat, % 22.3 ± 2.713.5 ± 3.26.5 ± 1.4−16.4 ± 2.4<0.0001
SMMP, %33.7 ± 0.934.1 ± 1.336.7 ± 0.81.7 ± 0.2<0.0001
FMP, %37.2 ± 1.438.9 ± 2.034.3 ± 1.3−3.0 ± 0.4 <0.0001
FPG, mmol/L5.3 ± 0.15.0 ± 0.1 5.2 ± 0.1−0.07 ± 0.150.001
2h PG, mmol/L7.5 ± 0.36.9 ± 0.3−0.59 ± 0.310.061
FINS, μU/mL22.5 ± 4.010.2 ± 0.8 11.8 ± 1.4 −11.5 ± 4.30.003
2h INS, μU/mL 134.2 ± 11.371.1 ± 8.2−57.2 ± 11.3<0.0001
HOMA IR 6.1 ± 1.52.3 ± 0.22.8 ± 0.4−3.6 ± 1.70.006
HOMA β235.7 ± 21.6140.3 ± 11.4136.2 ± 12.1−104.8 ± 18.3<0.0001
WBISI67.0 ± 6.9123.7 ± 12.854.2 ± 13.9<0.0001

Data are presented as mean ± standard error (SE). SFA: subcutaneous fat area; VFA: visceral fat area; SMMP: skeletal muscle mass percentage of whole body weight; FMP: fat mass percentage of whole body weight;. FPG: fasting plasma glucose; 2hPG: 2h postprandial glucose; FINS: fasting insulin; WBISI: whole body insulin sensitivity index. P: changes of sequential data within experiments from baseline to week 8. Significant difference observed versus baseline: ; .